📰 Nasdaq Cmmb News
Nasdaq Cmmb News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Cmmb. Real-time updates on events, politics, business and more.
March 25, 2024
Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories....
March 10, 2024
Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14, Zacks reports. During the same period in the previous year, the firm earned ($0.72) earnings per share. Chemomab Therapeutics Stock Performance Shares of CMMB stock […]
October 2, 2023
Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Free Report) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 37,400 shares, a decrease of 9.2% from the August 31st total of 41,200 shares. Based on an average daily volume of 56,700 shares, […]
August 14, 2023
Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Free Report) was the recipient of a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 56,200 shares, a decline of 43.3% from the July 15th total of 99,200 shares. Approximately 0.5% of the shares of the company are […]
August 13, 2023
Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Free Report) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 56,200 shares, a decline of 43.3% from the July 15th total of 99,200 shares. Approximately 0.5% of the shares of the stock are sold short. Based […]
July 18, 2023
Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Free Report) was the recipient of a large drop in short interest in June. As of June 30th, there was short interest totalling 93,100 shares, a drop of 69.1% from the June 15th total of 301,700 shares. Based on an average daily volume of 175,800 shares, the days-to-cover ratio […]
June 16, 2023
Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Rating) saw a large drop in short interest in May. As of May 31st, there was short interest totalling 326,500 shares, a drop of 22.8% from the May 15th total of 422,900 shares. Currently, 3.7% of the company’s stock are sold short. Based on an average trading volume of […]
June 1, 2023
Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Rating) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 422,900 shares, a decline of 7.3% from the April 30th total of 456,300 shares. Based on an average trading volume of 74,000 shares, the short-interest ratio is […]
May 15, 2023
Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Rating) was the recipient of a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 456,300 shares, a decline of 11.8% from the April 15th total of 517,400 shares. Approximately 4.9% of the shares of the company are short […]
April 19, 2023
Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Rating) – Oppenheimer issued their Q1 2024 earnings per share (EPS) estimates for shares of Chemomab Therapeutics in a research report issued to clients and investors on Monday, April 17th. Oppenheimer analyst J. Jones anticipates that the company will earn ($0.02) per share for the quarter. The consensus estimate […]